<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR79">
 <label>79.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Thachil</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Tang</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Gando</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Falanga</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Cattaneo</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Levi</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>DOACs and 'newer' haemophilia therapies in COVID-19</article-title>
  <source>J Thromb Haemost.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1111/jth.14841</pub-id>
  <?supplied-pmid 32558075?>
  <pub-id pub-id-type="pmid">32558075</pub-id>
 </element-citation>
</ref>
